MedChemExpress - Model Tebentafusp - 1874157-95-5
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A*02:01 (a melanoma-associated antigen). Tebentafusp guides T cells to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells[1][2].MCE products for research use only. We do not sell to patients.
Tebentafusp
MCE China：Tebentafusp
Brand：MedChemExpress (MCE)
Cat. No.HY-P99339
CAS：1874157-95-5
Synonyms：IMCgp100
Purity：99.90%
Storage：Please store the product under the recommended conditions in the Certificate of Analysis.
Shipping：Shipping with dry ice.
Description：Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A*02:01 (a melanoma-associated antigen). Tebentafusp guides T cells to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells.
In Vitro：Tebentafusp is an ImmTAC recognizing a peptide derived from the melanoma-specific protein, gp100, presented by HLA-A*0201[3]. Tebentafusp (31 pM, 82 pM, and 131 pM; 16 h) stimulates cytotoxic degranulation activity of PBMC against Mel526 cells rather than gp100-negative A375 cells[3]. Tebentafusp (100 pM; 0-50 h) mediates CD8+ T cell killing despite the presence of regulatory T cells via monitoring caspase 3/7 activation during 40-48 hr[3]. Tebentafusp (100 pM; 0-80 h) triggers cytolysis of melanoma cells by CD4+ T cell subpopulations[3]. Tebentafusp (1, 12, 31, 82, and 131 pM; 24 h or 96 h) increases granzyme B amount, and induces broad cytokine and chemokine release including in both CD4+ and CD8+ cells[3].
In Vivo：Tebentafusp (10 μg/kg; i.v.) inhibits tumor growth in mouse melanoma model[4].
Species：Humanized
Isotype：scFv-TR-Alpha_Beta-2
Hot selling product：Cedazuridine | γ-Glutamylhistidine | Batefenterol | Famotidine | Leucomethylene blue (mesylate) | Clomethiazole | Biliverdin Reductase A/BLVRA, Human (C-His) | Itraconazole-d5 | Acevaltrate | Deoxynyboquinone
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides
References：
[1]. Middleton MR, et al. Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. Clin Cancer Res. 2020 Nov 15;26(22):5869-5878. [Content Brief]
[2]. Dhillon S. Tebentafusp: First Approval. Drugs. 2022 Apr;82(6):703-710. [Content Brief]
[3]. Boudousquie C, et al. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells. Immunology. 2017 Nov;152(3):425-438. [Content Brief]
Brand introduction:
• MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world；
• More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas；
• The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects；
• Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services；
• It has a professional experimental center and strict quality control and verification system；
• Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products；
• The biological activity of the products has been verified by the experiments of customers in various countries；
• A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers；
• Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world；
• It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。